PTC Therapeutics operates within the complex rare disease and genetic disorders biopharmaceutical sector, putting it in direct competition with numerous clinical-stage and commercial biotechnology firms. Its primary competitors include companies developing targeted therapies, RNA-based treatments, and gene-modifying technologies for rare neuromuscular and metabolic conditions—such as Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and various other genomic medicine enterprises striving to bring innovative orphan drug treatments to global patient populations.